[HTML][HTML] Survival and immunotoxicities in association with sex-specific body composition patterns of cancer patients undergoing immune-checkpoint inhibitor therapy …
P Trinkner, S Günther, I Monsef, E Kerschbaum… - European Journal of …, 2023 - Elsevier
Background Imbalanced body composition is mechanistically connected to dysregulated
immune activities. Whether overweight/obesity or sarcopenia has an impact on treatment …
immune activities. Whether overweight/obesity or sarcopenia has an impact on treatment …
Gut microbiome and nutrition-related predictors of response to immunotherapy in cancer: making sense of the puzzle
C Hes, RT Jagoe - BJC Reports, 2023 - nature.com
The gut microbiome is emerging as an important predictor of response to immune
checkpoint inhibitor (ICI) therapy for patients with cancer. However, several nutrition-related …
checkpoint inhibitor (ICI) therapy for patients with cancer. However, several nutrition-related …
Voluntary exercise sensitizes cancer immunotherapy via the collagen inhibition-orchestrated inflammatory tumor immune microenvironment
Physical activity reduces cancer-associated mortality through multiple mechanisms,
including tumor immune microenvironment (TIME) reprogramming. However, whether and …
including tumor immune microenvironment (TIME) reprogramming. However, whether and …
Effect of cancer-related cachexia and associated changes in nutritional status, inflammatory status, and muscle mass on immunotherapy efficacy and survival in …
C Madeddu, S Busquets, C Donisi, E Lai, A Pretta… - Cancers, 2023 - mdpi.com
Simple Summary Immune checkpoint inhibitor (ICI)-based immunotherapy has dramatically
improved the survival of patients with advanced non-small cell lung cancer (NSCLC); …
improved the survival of patients with advanced non-small cell lung cancer (NSCLC); …
Sarcopenia was a poor prognostic predictor for patients with advanced lung cancer treated with immune checkpoint inhibitors
S Li, Z Liu, Y Ren, J Liu, S Lv, P He, Y Yang… - Frontiers in …, 2022 - frontiersin.org
Background It remains not well known whether skeletal muscle mass (SMM) loss has any
impact on the effectiveness of immune checkpoint inhibitors (ICIs) in patients with advanced …
impact on the effectiveness of immune checkpoint inhibitors (ICIs) in patients with advanced …
Sarcopenia as a determinant of the efficacy of immune checkpoint inhibitors in non-small cell lung cancer: a meta-analysis
B Ren, J Shen, Y Qian, T Zhou - Nutrition and Cancer, 2023 - Taylor & Francis
Objective The impact of pre-immunotherapy sarcopenia in patients with non-small cell lung
cancer (NSCLC) receiving immune checkpoint inhibitors (ICIs) is elusive. We performed a …
cancer (NSCLC) receiving immune checkpoint inhibitors (ICIs) is elusive. We performed a …
Association of computed tomography measures of muscle and adipose tissue and progressive changes throughout treatment with clinical endpoints in patients with …
Simple Summary The impact of sarcopenia (ie, progressive and generalised loss of skeletal
muscle mass) and obesity on survival are substantially investigated in cancer patients …
muscle mass) and obesity on survival are substantially investigated in cancer patients …
Effect of liver metastasis on the efficacy of immune checkpoint inhibitors in cancer patients: a systemic review and meta-analysis
BW Tian, CL Han, HC Wang, LJ Yan, ZN Ding… - Clinical & Experimental …, 2023 - Springer
Liver metastasis is a frequent phenomenon in advanced tumor disease. Immune checkpoint
inhibitors (ICIs) are a new class of therapeutics that can improve the prognosis of cancer …
inhibitors (ICIs) are a new class of therapeutics that can improve the prognosis of cancer …
Impact of BMI on the survival outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis
T Zhang, S Li, J Chang, Y Qin, C Li - BMC cancer, 2023 - Springer
Objectives ICIs have become the standard treatment for advanced NSCLC patients.
Currently, PD-L1 is the most widely useful biomarker to predict ICI efficacy, but the sensitivity …
Currently, PD-L1 is the most widely useful biomarker to predict ICI efficacy, but the sensitivity …
The impact of sarcopenia on the efficacy of PD-1 inhibitors in non-small cell lung cancer and potential strategies to overcome resistance
Z Liu, T Lei, Y Guo, C Zheng - Frontiers in Pharmacology, 2024 - frontiersin.org
Recent studies have revealed that sarcopenia can adversely affect the efficacy of PD-1
inhibitors in the treatment of non-small cell lung cancer (NSCLC). PD-1 inhibitors are …
inhibitors in the treatment of non-small cell lung cancer (NSCLC). PD-1 inhibitors are …